Stimulant-induced anxiety disorder including amphetamines, methamphetamine or methcathinone (Q40436): Difference between revisions
From determinar.ia.br - Determine suas informações
Created a new Item |
Changed label, description and/or aliases in pt-br, en |
||
| description / pt-br | description / pt-br | ||
Transtorno de ansiedade induzido por estimulantes, incluindo anfetaminas, metanfetamina e metcatinona mas excluindo cafeína, cocaína e catinonas sintéticas, é caracterizado por sintomas ansiosos (p. ex., apreensão ou preocupação, medo, sintomas fisiológicos de ativação autonômica excessiva, comportamento de evitação) que se desenvolvem durante ou logo após intoxicação por ou abstinência de estimulantes. A intensidade ou duração dos sintomas é consideravelmente maior do que sintomas ansiosos característicos da intoxicação por estimulantes ou abstinência de estimulantes. A quantidade e duração do uso de estimulantes devem ser capazes de produzir sintomas de ansiedade. Os sintomas não são mais bem explicados por um transtorno mental primário (p.ex., transtorno de ansiedade e relacionado ao medo, transtorno depressivo com sintomas ansiosos proeminentes), como pode ser o caso se os sintomas de ansiedade precederam o início do uso de estimulantes, se os sintomas persistem por um período de tempo considerável após a cessação do uso ou a abstinência de estimulantes, ou se há outra evidência de um transtorno mental primário preexistente com sintomas ansiosos (p. ex., história de episódios anteriores não associados ao uso de estimulantes). | |||
| description / en | description / en | ||
Stimulant-induced anxiety disorder including amphetamines, methamphetamine and methcathinone but excluding caffeine, cocaine and synthetic cathinones is characterised by anxiety symptoms (e.g., apprehension or worry, fear, physiological symptoms of excessive autonomic arousal, avoidance behaviour) that develop during or soon after intoxication or withdrawal due to stimulants. The intensity or duration of the symptoms is substantially in excess of anxiety symptoms that are characteristic of Stimulant intoxication or Stimulant withdrawal. The amount and duration of stimulant use must be capable of producing anxiety symptoms. The symptoms are not better explained by a primary mental disorder (e.g., an Anxiety and fear-related disorder, a Depressive disorder with prominent anxiety symptoms), as might be the case if the anxiety symptoms preceded the onset of the stimulant use, if the symptoms persist for a substantial period of time after cessation of the stimulant use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with anxiety symptoms (e.g., a history of prior episodes not associated with use of stimulants). | |||
Revision as of 06:14, 13 August 2026
Stimulant-induced anxiety disorder including amphetamines, methamphetamine and methcathinone but excluding caffeine, cocaine and synthetic cathinones is characterised by anxiety symptoms (e.g., apprehension or worry, fear, physiological symptoms of excessive autonomic arousal, avoidance behaviour) that develop during or soon after intoxication or withdrawal due to stimulants. The intensity or duration of the symptoms is substantially in excess of anxiety symptoms that are characteristic of Stimulant intoxication or Stimulant withdrawal. The amount and duration of stimulant use must be capable of producing anxiety symptoms. The symptoms are not better explained by a primary mental disorder (e.g., an Anxiety and fear-related disorder, a Depressive disorder with prominent anxiety symptoms), as might be the case if the anxiety symptoms preceded the onset of the stimulant use, if the symptoms persist for a substantial period of time after cessation of the stimulant use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with anxiety symptoms (e.g., a history of prior episodes not associated with use of stimulants).
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | 6C46.71 |
||
| English | Stimulant-induced anxiety disorder including amphetamines, methamphetamine or methcathinone |
Stimulant-induced anxiety disorder including amphetamines, methamphetamine and methcathinone but excluding caffeine, cocaine and synthetic cathinones is characterised by anxiety symptoms (e.g., apprehension or worry, fear, physiological symptoms of excessive autonomic arousal, avoidance behaviour) that develop during or soon after intoxication or withdrawal due to stimulants. The intensity or duration of the symptoms is substantially in excess of anxiety symptoms that are characteristic of Stimulant intoxication or Stimulant withdrawal. The amount and duration of stimulant use must be capable of producing anxiety symptoms. The symptoms are not better explained by a primary mental disorder (e.g., an Anxiety and fear-related disorder, a Depressive disorder with prominent anxiety symptoms), as might be the case if the anxiety symptoms preceded the onset of the stimulant use, if the symptoms persist for a substantial period of time after cessation of the stimulant use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with anxiety symptoms (e.g., a history of prior episodes not associated with use of stimulants). |
